JP2024524180A - インクレチン類似体の使用方法及びインクレチン類似体を含む組成物 - Google Patents

インクレチン類似体の使用方法及びインクレチン類似体を含む組成物 Download PDF

Info

Publication number
JP2024524180A
JP2024524180A JP2023578701A JP2023578701A JP2024524180A JP 2024524180 A JP2024524180 A JP 2024524180A JP 2023578701 A JP2023578701 A JP 2023578701A JP 2023578701 A JP2023578701 A JP 2023578701A JP 2024524180 A JP2024524180 A JP 2024524180A
Authority
JP
Japan
Prior art keywords
weekly dose
dose
ggg
week
weekly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023578701A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024524180A5 (enExample
Inventor
コスクン，タマー
ミリチェビッチ，ズヴォンコ
ウルヴァ，シュヴェータ
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2024524180A publication Critical patent/JP2024524180A/ja
Publication of JP2024524180A5 publication Critical patent/JP2024524180A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2023578701A 2021-06-23 2022-06-22 インクレチン類似体の使用方法及びインクレチン類似体を含む組成物 Pending JP2024524180A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163213956P 2021-06-23 2021-06-23
US63/213,956 2021-06-23
PCT/US2022/034437 WO2022271767A1 (en) 2021-06-23 2022-06-22 An incretin analog for use in glycemic control and weight management

Publications (2)

Publication Number Publication Date
JP2024524180A true JP2024524180A (ja) 2024-07-05
JP2024524180A5 JP2024524180A5 (enExample) 2024-12-02

Family

ID=82608370

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023578701A Pending JP2024524180A (ja) 2021-06-23 2022-06-22 インクレチン類似体の使用方法及びインクレチン類似体を含む組成物

Country Status (11)

Country Link
US (3) US12496329B2 (enExample)
EP (1) EP4358994A1 (enExample)
JP (1) JP2024524180A (enExample)
KR (1) KR20240024936A (enExample)
CN (1) CN117915939A (enExample)
AU (2) AU2022298662B2 (enExample)
BR (1) BR112023027321A2 (enExample)
CA (1) CA3223313A1 (enExample)
IL (1) IL309604A (enExample)
MX (3) MX2024000213A (enExample)
WO (1) WO2022271767A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102812908B1 (ko) * 2019-08-19 2025-05-28 일라이 릴리 앤드 캄파니 인크레틴 유사체의 제조 방법
CN117320740A (zh) * 2021-02-17 2023-12-29 伊莱利利公司 Gip/glp1双重激动剂治疗方法
WO2026037397A1 (zh) * 2024-08-16 2026-02-19 江苏恒瑞医药股份有限公司 Glp-1类似物的医药用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019125938A1 (en) * 2017-12-21 2019-06-27 Eli Lilly And Company Incretin analogs and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2548275T3 (es) 2010-03-01 2015-10-15 Eli Lilly And Company Dispositivo de inyección automático con mecanismo de retardo que incluye un elemento de empuje de funcionamiento doble
KR102589234B1 (ko) 2017-11-21 2023-10-16 일라이 릴리 앤드 캄파니 둘라글루티드를 함유하는 조성물 및 사용 방법
TWI767095B (zh) 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
CA3177693A1 (en) 2019-04-05 2020-10-05 Eli Lilly And Company Therapeutic uses of dulaglutide
TW202140058A (zh) 2020-01-30 2021-11-01 美商美國禮來大藥廠 提派肽（ｔｉｒｚｅｐａｔｉｄｅ）之治療用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019125938A1 (en) * 2017-12-21 2019-06-27 Eli Lilly And Company Incretin analogs and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DIABETES OBES. METAB., vol. 22, JPN6025007593, 2020, pages 938 - 946, ISSN: 0005738387 *
MOLECULAR METABOLISM, vol. 18, JPN6025007592, 2018, pages 3 - 14, ISSN: 0005738386 *
新医薬品の臨床評価に関する一般指針について, vol. 薬新薬第43号, JPN3017001136, 29 June 1992 (1992-06-29), JP, ISSN: 0005738385 *

Also Published As

Publication number Publication date
US20260091088A1 (en) 2026-04-02
US20240325498A1 (en) 2024-10-03
EP4358994A1 (en) 2024-05-01
KR20240024936A (ko) 2024-02-26
AU2022298662A1 (en) 2024-01-18
CN117915939A (zh) 2024-04-19
IL309604A (en) 2024-02-01
AU2025220848A1 (en) 2025-09-11
US20260091087A1 (en) 2026-04-02
MX2024000213A (es) 2024-04-16
MX2025012714A (es) 2025-11-03
AU2022298662B2 (en) 2025-06-05
BR112023027321A2 (pt) 2024-03-12
US12496329B2 (en) 2025-12-16
MX2025012713A (es) 2025-11-03
WO2022271767A1 (en) 2022-12-29
CA3223313A1 (en) 2022-12-29

Similar Documents

Publication Publication Date Title
AU2022291585B2 (en) Methods of using a GIP/GLP1 co-agonist for therapy
Zinman et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+ TZD)
US12496329B2 (en) Methods of using and compositions including an incretin analog
WO2024006662A1 (en) Tirzepatide compositions and use
JP2024513754A (ja) インクレチン類似体含有組成物及びその使用
EA053233B1 (ru) Способы применения и композиции, включающие аналог инкретина
BR122025000167A2 (pt) Uso de um polipeptídeo, composição que compreende trirreceptor ggg, e dispositivo
US20240366728A1 (en) Treatment of Diabetes Mellitus
TWI919251B (zh) 使用gip/glp1共促效劑之療法
JP2025518758A (ja) 療法のためのｇｃｇ／ｇｌｐ１コアゴニストを使用する方法
AU2026202976A1 (en) Methods of using a GIP/GLP1 co-agonist for therapy
HK40127982A (zh) 使用gip/glp1共激动剂用於治疗的方法
HK40128497A (zh) 使用gip/glp1共激动剂用於治疗的方法
HK40128498A (zh) 使用gip/glp1共激动剂用於治疗的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241122

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20241122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260224